Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Bright Peak Therapeutics has emerged from stealth with $35 million to develop synthetic protein therapeutics. The firm’s first project is an improved version of interleukin-2, a cytokine that is being hotly pursued as a cancer immunotherapy. Based in Switzerland, Bright Peak was incubated and backed by the investment firmVersant Ventures. It’s based on technology developed by ETH Zurich organic chemist Jeffrey Bode, who came up with a simple way to stitch together amino acid sequences.
This article has been sent to the following recipient: